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I.
INTRODUCTORY
LECTURE - ABSTRACT
PEDIATRIC HEMATOPOIETIC STEM
CELL TRANSPLANTATION IN PO-
LAND - DEVELOPMENT AND CUR-
RENT STATUS
J. Wachowiak1 , U. Radwanska1,
J. Bogus~awska-Jaworska2, J. Kowalczyk3,
A. Chybicka2, D. Boruczkowski1,
E. Gorczynska2, K. Ka~wak2, M. Leda1,
A. Pieczonka1, M. S~ociak2, J. Toporski2,
D. Turkiewicz2, B. W6jcik3,
A. Zaucha-Prazm03 on behalf of the Polish
Pediatric Leukemia / Lymphoma Study
Group (PPLLSG)
1Departments of Pediatric Hematology
and Oncology in Poznan, 2Wrodaw
and 3Lublin
PPLLSG transplant centers: within
PPLLSG three transplant centers are ac-
tive, i.e. in Poznan (since 1989), in Wrodaw
(since 1994) and in Lublin (since 1998).
No. of transplant rooms: number
of transplant rooms was growing from
1 in 1989 to 19 in 2000 (12 in Wrodaw,
4 in Lublin, 3 in Poznan).
No. of patients and type (allo/auto)
of HSCT per year: 1989 - 1/0 (Poznan);
1990 to 1992 - 5/0 (Poznan); 1993 - 6/0
(Poznan); 1994 - 12 (1/5 in Wrodaw,
6/0 in Poznan); 1995 - 17 (1/6 in Wroclaw,
1% in Poznan); 1996 - 34 (9/15 in Wro-
claw, 1% in Poznan); 1997 - 37 (5/21
in Wroclaw, 11/0 in Poznan); 1998 - 45
(8/21 in Wroclaw, 14/0 in Poznan, 0/2
in Lublin); 1999 - 66 (14/16 in Wrodaw,
1/19 in Lublin, 16/0 in Poznan); 2000 - 84
(22/21 in Wrodaw, 16/5 in Poznan, 6/14
in Lublin). Total number of patients and ty-
pe of transplant: 317 [allo 172 (54,3%)/
auto 145 (45,7%)].
Indications for allo-HSCT: ALL 62
(36,0%), AML 31 (18,0%), CML 25
(14,5%), SAA 20 (11,6%), MDS 13 (7,6%),
B-DA 6 (3,5%), NHL 5 (2,9%), SCID 5
(2,9%), FA 4 (2,3%), Ewing s. 1 (0,6%),
i.e. malignant diseases 137 (79,7%)
and non-malignant diseases 35 (20,3%)
(congenital 15, acquired 20).
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Indications for auto-HSCT: NHL 39
(26,9%), ALL 21 (14,5%), AML 21 (14,5%),
RMS 16 (11,0%), NBL 15 (10,3%), Ewing
s. 11 (7,6%), HD 9 (6,2%), CML 2 (1,4%),
other solid tumors 11 (7,6%), i.e. leukemia
+ lymphoma 92 (63,4%) and solid tumors
53 (36,6%).
Stem cell sources for allo-HSCT: BM
152 (88,4%), PBSC 17 (79,9%) - in Wro-
daw since 1996, BM+PBSC 2 (1,2%), CB 1
(0,6%) - in Poznan since 2000.
Stem cell sources for auto-HSCT: PBSC
124 (85,5%), BM+PBSC 15 (10,3%), BM 6
(4,1%).
Donor type for allo-HSCT: MSD 148
(86,0%), MMRD 18 (10,5%) - in Wrodaw
since 1996, MUD 6 (3,5%) - in Wrodaw
since 2000.
Conclusion: There was significant de-
velopment of HSCT within PPLLSG cen-
ters in the nineties. However, in context
of 1500 new cases of cancer diagnosed
and treated each year in these centers as
well as in context of contemporary role
of HSCT in cancer therapy in children,
the number of auto- and allo-HSCT
(especially from alternative donors
and from alternative sources) performed
in pediatric centers is still too low. Further
increase of HSCT number is necessary
to fulfil therapeutical standards and to im-
prove treatment results in Polish children
with cancer.
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1.
SEVERE NEUROLOGICAL EVENTS
(SNE) AFTER BONE MARROW
TRANSPLANTATION (BMT) IN CHIL-
DREN
M. Faraci1 , R. Haupt2, S. Dallorso1,
E. Lanino\ G.Morreale1, M.G. Calev02,
C. Manzitti1, P. Fondel1i3, R. Gagger04,
G. Dini1
1Heamatology/Oncology Dept; 2Scientific
Directorate; 3Neuroradiology Dept;
4Neurology Dept; G. Gaslini Children's
Hospital - Genova, Italy
To evaluate incidence, risk factors
and outcome of SNE after BMT,
815
we retrospectively evaluated 272 (169 M,
103 F) consecutive children that between
June 1985 and January 2001 underwent
BMT at the "G. Gaslini" Institute. Subjects
with solid tumor were excluded. Their
median age at transplant was 8 years
(range 2 mos. - I 9 yr.), and the source
of stem cells was autologous (A), related
donor (RD)., and unrelated donor (UD)
in 87, 115 and 70 subjects, respectively.
166 children received total body irradiation
(TBI) as part of the conditioning regimen;
63 received Busulfan while 43 were
treated with other drugs; finally, 54 chil-
dren received cranial prophylactic
irradiation (CPI) (1800 cGy) during front
line treatment before BMT.
A total of 41 SNE were observed
in 37 children (18 M, 19 F); their median
age at BMT was 10 years (range 2 - 16 yr.).
Neurological symptoms occurred after
a median time of 92 days (range 5 - 3203)
The source of HSCT was UD-BM, RD-BM,
and A-BM in 19, 16, and 2 cases respe-
ctively.). Ten of them received CPI before
BMT. Neurological symptoms were: seizu-
res (n=20), changes of mental status
and coma (n=12), motor or sensitive
defects (n=6), progressive loss of cogni-
tive functions (n=3), clonus and myoclonus
(n=2) and visual impairment (n=1). Causes
of neurological symptoms were attributed
to CSA toxicity (CSA-t) in 21 pt. (77%),
to irradiation or chemotherapy injury (IC-i)
in 7 (2.6%), to CNS infections (CNS-I)
in 7 (2.6%), to CNS hemorrhages in 3 pt.
(1.1 %) and to immunomediated
pathogenesis in the remaining 3 (1.1 %).
CSA-t occurred in 21 out of 185 patients
receiving immunosuppressive therapy.
Onset of symptoms was after a median
of 96 days (range 20 - 370 days) after
BMT. When CSA was discontinued, a com-
plete resolution of SNE was observed in all
cases. The 7 IC-i occurred between
1 month and 7 years after BMT. Mental
deterioration and lor coma were observed
in 5, clonus and dysarthria in one and
visual impairment in another. CNS-I were
observed in 7 pt. and were mostly of viral
origin (2 cases of EBV, and 1 of CMV,
HHV6 and adenovirus, respectively),
whereas the 2 remaining cases had
neurotoxoplasmosis and aspergillosis.
The 3 CNS hemorrhages occurred 30, 50
S16
and 250 days from BMT, respectively.
Finally the 3 immunomedia-ted SNE were
due to a demyelinating leucoencephalo-
pathy in the context of ex-tensive chronic
GvHD in2 cases; and to a Guillain-Barre
syndrome in the remainning one.
Preliminary analysis shows that type
of BMT (p<0.01) and TBI (p<0.05) are risk
factors for SNE; gender, age at BMT,
and CPI were not associated with
an increased risk of SNE. Risk factors
for the 5 different types of. SNE will
be presented and discussed.
2.
LATE ONSET IDIOPATHIC
THROMBOCYTOPENIC PURPURA
CORRELATES WITH RAPID B CELL
RECOVERY IN CHILDREN AFTER
ALLOGENEIC TRANSPLANTS FROM
ALTERNATIVE DONORS. SINGLE
CENTRE EXPERIENCE
K. Kalwak, D. Wojcik, E. Gorczyr'iska,
J. Toporski, D. Turkiewicz, M. Sfociak,
E. Grazyr'iska-Latos,
J. Bogustawska-Jaworska, A. Chybicka
Department of Pediatric
Hematology/Oncology, University
of Medicine Wrodaw (EBMT CIC number
817), Poland
Late onset steroid-resistant idiopathic
thrombocytopenic purpura (ITP) after
allogeneic transplant remains rare yet
important clinical problem. Two cases
of ITP late post transplant are reported
and discussed.
Patient UPN 176. 16-year old girl with
MDS-RA underwent allogeneic PBSCT
from male matched unrelated donor
in August 2000. She was conditioned with
Bu 16mg/kg, Cy 200 mg/kg and ATG
20 mg/kg. GvHD prophylaxis consisted
of CsA, MTX and methylprednisolone
(MP). Hematological recovery was
adequate: ANC > 0.5 Gil on day +16,
platelets> 50 Gil on day +33. Mild aGvHD
1° resolved quickly. No complications were
observed until January 2001 (147 days
after transplantation), when she developed
ITP with a platelet count of 7 Gil and
numerous petechiae. BM biopsy confirmed
trilineage engratfment with almost 100%
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